It is a multicenter randomized double-blind study conducted over three years, which gives it high scientific quality, although it would be interesting to increase the number of cases and placebo, given that it is a very prevalent disease.

This medication has been approved for some years in children with obesity and type 2 diabetes over 10 years of age, with good results both at the research and clinical levels. To date there are new medications in this age group in obese children without type 2 diabetes with better results, so liraglutide is being left in the background as a treatment option.

However, in children under 10 years of age there is currently no approved medication unless it is monogenic obesity, which has its specific medication, and there are few short-term studies with liraglutide in this age group, so the new NEJM publication offers us a new possibility of treatment in children under 10 years of age who do not respond to diet and original exercise, justified, that we have experience in its use and we know that it is safe and works in children of older ages.

[Regarding possible important imitations of the study].

Obesity always encompasses adherence, environmental, economic, and social biases. They all play against the results and yet they have been good. To this must be added the need to extend the n, as discussed above, and the need to continue testing new drugs that have shown superiority at other ages versus the one being presented in this study.